Intra-Cellular Therapies Settles CAPLYTA® (lumateperone) Patent Litigation with Sandoz
10. Januar 2025 06:30 ET
|
Intra-Cellular Therapies, Inc.
BEDMINSTER, N.J., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics...
Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
06. Januar 2025 08:00 ET
|
Intra-Cellular Therapies, Inc.
BEDMINSTER, N.J., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for...
Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting
11. Dezember 2024 08:00 ET
|
Intra-Cellular Therapies, Inc.
Presentations complement topline data with new data from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy for the treatment of major depressive disorder Data...
Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy
03. Dezember 2024 07:30 ET
|
Intra-Cellular Therapies, Inc.
The sNDA submission is based on positive results from Studies 501 and 502 demonstrating CAPLYTA’s robust antidepressant efficacy and favorable safety and tolerability profileCAPLYTA, if approved as an...
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
19. November 2024 08:00 ET
|
Intra-Cellular Therapies, Inc.
BEDMINSTER, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for...
Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress
07. November 2024 08:00 ET
|
Intra-Cellular Therapies Inc.
Presentations include results from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) ...
Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia
05. November 2024 07:00 ET
|
Intra-Cellular Therapies Inc.
The efficacy and safety of CAPLYTA (lumateperone) as a maintenance treatment in adults with schizophrenia was demonstrated in a randomized withdrawal trial The study demonstrated a statistically...
Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance
30. Oktober 2024 07:30 ET
|
Intra-Cellular Therapies Inc.
CAPLYTA Q3 2024 net product sales were $175.2 million, compared to $125.8 million for the same period in 2023, representing a 39% increase CAPLYTA’s strong prescription uptake continues: Q3 2024...
Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast
17. Oktober 2024 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress
23. September 2024 08:00 ET
|
Intra-Cellular Therapies Inc.
Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) Poster...